Treats CMV retinitis. ANDA 216602, held by Amneal. Foscarnet Sodium.
As of Nov 16, 2026, ANDA 216602 (Foscarnet Sodium), held by Amneal, was first approved by FDA on Mar 1, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS CMV Retinitis Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 1, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Foscarnet Sodium6GM/250ML (24MG/ML) · solution;intravenous | Foscarnet Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters